Lewis Nasr - Concepedia

Author

Lewis Nasr

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

L. F. Nasr, L.F. Nasr, Lewis F. Nasr, Lewis F Nasr, Lewis F. Nasr, Lewis Fady Nasr, Lewis Nasr

Publications

512

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Albert Einstein College of Medicine Augusta University Health St. Jude Children's Research Hospital

About

Lewis Nasr is an author at The University of Texas MD Anderson Cancer Center specializing in public health, oncology, and social computing.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	14
2	Nursing	1	1	14
3	Public Health	1	1	14
4	Communication	1	1	14
5	Health Informatics	1	1	14

Lewis Nasr

Publications

360

Citations

H-Index

Page 1

	Year	Citations
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Journal of Clinical Oncology	2024	120
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL Hagop M. Kantarjian, Nicholas J. Short, Fadi Haddad, Journal of Clinical Oncology	2024	58
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents Nicholas J. Short, Muharrem Müftüoğlu, Faustine Ong, Journal of Hematology & Oncology	2023	48
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia Nicholas J. Short, Elias Jabbour, Nitin Jain, Blood Advances	2024	28
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL Yaqi Zhao, Nicholas J. Short, Hagop M. Kantarjian, Blood	2024	28
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia Nicholas J. Short, Elias Jabbour, Trevor Jamison, Clinical Lymphoma Myeloma & Leukemia	2023	18
AI-based online chat and the future of oncology care: a promising technology or a solution in search of a problem? Joseph Kassab, Lewis Nasr, Georges Gebrael, Frontiers in Oncology ChatbotCancer ManagementEpidemiology Of CancerPathologyCommunication	2023	14
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia Elias Jabbour, Fadi Haddad, Koji Sasaki, Cancer	2024	14
Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Blood	2023	12
A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL). Nicholas J. Short, Elias Jabbour, Nitin Jain, Journal of Clinical Oncology	2023	10

Page 1